definiens: means any two or more of the foregoing ; means any one of the BCMA Product, GD2 Product, Logic Gate Product, RQR8 Product, TRBC1/2 Product, NSGProduct, ZipCAR Product, and where the [ * * * ] Option has been exercised, [ * * * ] Product, and means any two ormore of the foregoing ; has the meaning set out in Clause 8.3 ; or means [COMPANY] or UCLB, or both [COMPANY] and UCLB, as the context requires, including their respective successors in title, permitted assignees and transferees from time to time ( if any ) ; means the deed of assignment between the Parties in respect of the Assigned Patents dated on the Third AmendmentDate ; means those professional service fees and costs reasonably charged by a Third Party for the provision of patentfiling, prosecution ( including defending oppositions and interferences ), maintenance and renewal services with respect to the applicable LicensedPatent, including all official fees, charges and surcharges properly incurred in the provision of such services ; means all patent rights, claims in any patent right, applications for patents and the right to apply for patent rights in any part ofthe world including all divisionals, reissues, extensions, substitutions, conﬁrmations, registrations, revalidations, additions, continuations in - partand any supplementary protection certiﬁcates or patent term extensions and where referred to in the context of a schedule hereto shall includeall patent rights from time to time derived from, claiming priority from, issued or granted from those patent rights listed in such schedule ; has the meaning set out in Clause 15.1 ; means those clinical studies identified and briefly described in Schedule 7 ; means lymphoma of CNS cells that has originated within the central nervous system as the primary site of thelymphoma, as opposed to a secondary lymphoma of the CNS ; means any one of the Original Programs, the Additional Programs or the CAT19 Program, and means anycombination of two or more of the Original Programs, Additional Programs and the CAT19 Program, as the context requires ; means the Original Program IP, the Additional Program IP, the CAT19 Program IP and the CAROUSEL Program IP ; means one of the BCMA Licence, [ * * * ] Licence ( if [COMPANY] exercises its rights under Clause 2.5 ), GD2 Licence, Logic GateLicence, NSG Licence, RQR8 Licence, TRBC1/2 Licence, ZipCAR Licence, ccCAR Licence, Epitope Tag Licence, iCAR Licence, RapaiCASP9Licence, Retrostim Licence, TetCAR Licence, ZAP - CAR Licence, CAT19 Licence, TRBC2 Dx Licence and CAT19 CNS Licence ; means those materials forming part of the Program IP ; has the meaning set out in Clause 18.8 ; or means a period of three calendar months each commencing on 31 March, 30 June, 30 September or 31 December ; has the meaning set out in Clause 2.2.9 ; means any product or therapy which, were it not for the licence to RapaiCASP9 Patent Rights granted hereunder or theassignment to [COMPANY] ( or subsequent assignment or licence grant to an Assignee Entity ) of the RapaiCASP9 Patent Rights, would otherwiseinfringe the RapaiCASP9 Patent Rights in the relevant country of sale ; means the program of research deﬁned in Schedule 1 under the title RapaiCASP9 Program as conducted prior to theAmendment Date ; means excluding Manufacturing Know - How, ( i ) those patent applications listed in Schedule 2 under the titleRapaiCASP9 Patents and all Patent Rights derived therefrom ( ) ; ( ii ) the Know - How described in Schedule 2under the title RapaiCASP9 Know - How ; and ( iii ) the materials listed in Schedule 2 under the title RapaiCASP9 Materials together with all IP inthe same ; has the meaning set out in Clause 20.1 ; 11CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [ * * * ], HAS BEEN OMITTED BECAUSE IT IS NOTMATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED